Doctors have learnt how to treat COVID-19
COVID-19 is not one disease but many different ones. What all these diseases have in common is that the patient is infected with the SARS-CoV-2 virus.
It is not necessarily the virus that has caused the disease. According to the CDC, a maximum of six percent of deaths are directly attributable to the virus.
The heated debates about whether one or the other treatment cures COVID-19 or not leads nowhere because everyone can be right. Some types of COVID-19 are prevented or cured by Ivermectin, others by chloroquine, others by hydroxychloroquine, others by dexamethasone, others by budesonide, pregnenolone and other types of other corticosteroids. Others by tocilizumab and some variants may need a cocktail of these and additional agents for specific underlying deficiencies (vitamin deficiency) or conditions like high blood pressure, diabetes, cancer.
The first WHO message adopted by most international authorities which still seems to have a grip on the debate was: there is no cure for Covid-19.
Really scary. And it created unmatched panic. And it is true that there is no specific treatment because there is no specific disease COVID-19. But today, most doctors have learned to treat COVID-19 patients, with or against the consent of the authorities.
There are treatments and cures - in most cases successful - for all the diseases that go by the name COVID-19. Although the vaccines could not stop the spread of the virus, fewer and fewer people are dying. Many are still infected - even the vaccinated - but few die.
All authorities say that it is the vaccines that protect. Few doctor dares to admit the use of illicit medicines.
Contrary to what the WHO and other authorities initially claimed and largely maintain, there are a number of different medicines that help with COVID-19. And the medicines differ because COVID-19 is a number of different diseases.
The latest example is the drug tocilizumab, which is approved for rheumatoid arthritis, but has now been widely used to treat COVID-19.
This use has been initiated by doctors on the floor and is not seen lightly by the authorities. The use outside the indication (off-label) has been so great that the pharmaceutical company Roche has released information that there will be a global shortage of the drug Actemra / Roactemra (tocilizumab) in the coming months. It is currently approved for treatment of rheumatoid arthritis but is also considered a potential treatment for COVID-19. Following Roche's press release, the World Health Organization (WHO) has also expressed concern about the shortage.
Demand for the drug has increased to unmatched levels globally because it has been widely used to treat patients with severe or critical COVID-19, Roche writes in a press release. In 2021, the company has increased its deliveries of the drug by 100 percent compared to before the pandemic, which has led to restrictions in both production capacity and raw material supply.
WHO has accepted reality and, together with the global health initiative Unitaid, calls on Roche to ensure a fair distribution of the drug to all countries, including low- and middle-income countries. The WHO is also seeking expressions of interest from other pharmaceutical companies to increase the number of manufacturers of the drug and thereby be able to increase global deliveries.
There is also a shortage of tocilizumab in Sweden. According to the Medical Products Agency's list of residual listings, there is an ongoing shortage, which started on 2 August and is expected to last until 19 of September. There is also a forecast for a future shortage from 5 of September, which is expected to last until October 8.
Other authorities are also forced to revise their positions. The European Medicines Agency (EMA) recently launched an investigation into the use of tocilizumab for treatment of COVID-19. In the United States, tocilizumab has received emergency approval for patients with COVID-19 but the permission is limited to those patients who hospitalized and are already being treated with corticosteroids and are in need of oxygen or respiratory care.
In view of the surprising shortages, it can be assumed that individual doctors have gone beyond the authorities' recommendations, or are ahead, as they do for a large number of other medicines. The result is, gratifyingly, a globally greatly reduced morbidity and reduced mortality rate for those infected with SARS-CoV-2. Source about tocilizumab: https://www.lakemedelsvarlden.se/pandemin-skapar-global-brist-pa-ra-lakemedel/?link_id=Bt82kaADZ6Zljf